Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.

Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14.

PMID:
29735156
2.

Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.

Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative* and the PREVENT-AD Research Group.

Brain. 2018 Jun 1;141(6):1871-1883. doi: 10.1093/brain/awy093.

3.

Alterations in cholesterol metabolism-related genes in sporadic Alzheimer's disease.

Picard C, Julien C, Frappier J, Miron J, Théroux L, Dea D; United Kingdom Brain Expression Consortium and for the Alzheimer's Disease Neuroimaging Initiative, Breitner JCS, Poirier J.

Neurobiol Aging. 2018 Jun;66:180.e1-180.e9. doi: 10.1016/j.neurobiolaging.2018.01.018. Epub 2018 Feb 9.

PMID:
29503034
4.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

PMID:
29482212
5.

Author response: Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Breitner JCS.

Neurology. 2018 Feb 13;90(7):343. doi: 10.1212/WNL.0000000000004959. No abstract available.

PMID:
29440548
6.

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.

Tuwaig M, Savard M, Jutras B, Poirier J, Collins DL, Rosa-Neto P, Fontaine D, Breitner JCS; PREVENT-AD Research Group.

J Alzheimers Dis. 2017;60(4):1589-1600. doi: 10.3233/JAD-170545.

7.

Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group.

Neurology. 2017 Jul 25;89(4):327-335. doi: 10.1212/WNL.0000000000004159. Epub 2017 Jun 28.

8.

Comment: MCI trials-Categorical "square pegs" in dimensional "round holes"?

Breitner JCS.

Neurology. 2017 May 2;88(18):1757. doi: 10.1212/WNL.0000000000003893. Epub 2017 Apr 5. No abstract available.

PMID:
28381505
9.

Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model.

Cavanagh C, Tse YC, Nguyen HB, Krantic S, Breitner JC, Quirion R, Wong TP.

Neurobiol Aging. 2016 Nov;47:41-49. doi: 10.1016/j.neurobiolaging.2016.07.009. Epub 2016 Jul 25.

10.

How can we really improve screening methods for AD prevention trials?

Breitner JCS.

Alzheimers Dement (N Y). 2016 Feb 2;2(1):45-47. doi: 10.1016/j.trci.2015.12.004. eCollection 2016 Jan. Review. No abstract available.

11.

Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).

Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.

J Prev Alzheimers Dis. 2016;3(4):236-242. doi: 10.14283/jpad.2016.121.

PMID:
29199324
12.

'Alzheimer's Progression Score': Development of a Biomarker Summary Outcome for AD Prevention Trials.

Leoutsakos JM, Gross AL, Jones RN, Albert MS, Breitner JCS.

J Prev Alzheimers Dis. 2016;3(4):229-235. doi: 10.14283/jpad.2016.120.

13.

Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease.

Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group.

Sci Data. 2015 Oct 13;2:150043. doi: 10.1038/sdata.2015.43. eCollection 2015.

14.

Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.

Chuang YF, An Y, Bilgel M, Wong DF, Troncoso JC, O'Brien RJ, Breitner JC, Ferruci L, Resnick SM, Thambisetty M.

Mol Psychiatry. 2016 Jul;21(7):910-5. doi: 10.1038/mp.2015.129. Epub 2015 Sep 1.

15.

Comment: Yet another "disconnect" between amyloid and Alzheimer disease?

Breitner JC.

Neurology. 2015 Aug 25;85(8):698. doi: 10.1212/WNL.0000000000001871. Epub 2015 Jul 24. No abstract available.

PMID:
26208958
16.

Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages.

Colby-Milley J, Cavanagh C, Jego S, Breitner JC, Quirion R, Adamantidis A.

PLoS One. 2015 Jun 15;10(6):e0130177. doi: 10.1371/journal.pone.0130177. eCollection 2015.

17.

Encouraging trends toward reduced risk of Alzheimer disease: What's good for the heart is good for the brain.

Breitner JCS, Galasko D.

Neurol Clin Pract. 2015 Jun;5(3):190-192. doi: 10.1212/CPJ.0000000000000110. No abstract available.

18.

Neuroinflammation in Alzheimer's disease.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.

Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. Review.

19.

Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factors.

Barucker C, Sommer A, Beckmann G, Eravci M, Harmeier A, Schipke CG, Brockschnieder D, Dyrks T, Althoff V, Fraser PE, Hazrati LN, George-Hyslop PS, Breitner JC, Peters O, Multhaup G.

J Alzheimers Dis. 2015;44(2):613-24. doi: 10.3233/JAD-141902.

PMID:
25318543
20.

Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study.

Chuang YF, Breitner JCS, Chiu YL, Khachaturian A, Hayden K, Corcoran C, Tschanz J, Norton M, Munger R, Welsh-Bohmer K, Zandi PP; Cache County Investigators.

Neurobiol Aging. 2014 Nov;35(11):2429-2435. doi: 10.1016/j.neurobiolaging.2014.05.002. Epub 2014 May 9.

21.

Observations on DSM-5 Mild Neurocognitive Disorder vs. its predecessor, Mild Cognitive Impairment.

Breitner JC.

Acta Psychiatr Scand. 2015 Jan;131(1):15-7. doi: 10.1111/acps.12300. Epub 2014 Jun 9. No abstract available.

PMID:
24909394
22.

Mild cognitive impairment and progression to dementia: new findings.

Breitner JC.

Neurology. 2014 Jan 28;82(4):e34-5. doi: 10.1212/WNL.0000000000000158. No abstract available.

PMID:
24470608
23.

Three Cardinal Lessons from ADAPT - 10 Years on.

Breitner JCS, Lyketsos CG.

J Prev Alzheimers Dis. 2014;1(3):176-180. doi: 10.14283/jpad.2014.31.

PMID:
29251745
24.

An open science resource for establishing reliability and reproducibility in functional connectomics.

Zuo XN, Anderson JS, Bellec P, Birn RM, Biswal BB, Blautzik J, Breitner JC, Buckner RL, Calhoun VD, Castellanos FX, Chen A, Chen B, Chen J, Chen X, Colcombe SJ, Courtney W, Craddock RC, Di Martino A, Dong HM, Fu X, Gong Q, Gorgolewski KJ, Han Y, He Y, He Y, Ho E, Holmes A, Hou XH, Huckins J, Jiang T, Jiang Y, Kelley W, Kelly C, King M, LaConte SM, Lainhart JE, Lei X, Li HJ, Li K, Li K, Lin Q, Liu D, Liu J, Liu X, Liu Y, Lu G, Lu J, Luna B, Luo J, Lurie D, Mao Y, Margulies DS, Mayer AR, Meindl T, Meyerand ME, Nan W, Nielsen JA, O'Connor D, Paulsen D, Prabhakaran V, Qi Z, Qiu J, Shao C, Shehzad Z, Tang W, Villringer A, Wang H, Wang K, Wei D, Wei GX, Weng XC, Wu X, Xu T, Yang N, Yang Z, Zang YF, Zhang L, Zhang Q, Zhang Z, Zhang Z, Zhao K, Zhen Z, Zhou Y, Zhu XT, Milham MP.

Sci Data. 2014 Dec 9;1:140049. doi: 10.1038/sdata.2014.49. eCollection 2014.

25.

What should we do if we were wrong and Alzheimer was right?

Breitner JC.

Int Psychogeriatr. 2014 Jan;26(1):3-6. doi: 10.1017/S1041610213001749. Epub 2013 Oct 18. No abstract available.

PMID:
24135193
26.

Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.

Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate AM, Norton MC, Green RC, Munger RG, Breitner JC, Welsh-Bohmer KA, Lyketsos C, Tschanz J, Kauwe JS; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 May;10(3):366-71. doi: 10.1016/j.jalz.2013.02.010. Epub 2013 May 30.

27.

Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial.

Reckess GZ, Brandt J, Luis CA, Zandi P, Martin B, Breitner JC; ADAPT Research Group.

J Alzheimers Dis. 2013;36(3):433-43. doi: 10.3233/JAD-130113.

28.

A hierarchy of predictors for dementia-free survival in old-age: results of the AgeCoDe study.

Luck T, Riedel-Heller SG, Luppa M, Wiese B, Bachmann C, Jessen F, Bickel H, Weyerer S, Pentzek M, König HH, Prokein J, Eisele M, Wagner M, Mösch E, Werle J, Fuchs A, Brettschneider C, Scherer M, Breitner JC, Maier W.

Acta Psychiatr Scand. 2014 Jan;129(1):63-72. doi: 10.1111/acps.12129. Epub 2013 Mar 22.

PMID:
23521526
29.

Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study.

Shao H, Breitner JC, Whitmer RA, Wang J, Hayden K, Wengreen H, Corcoran C, Tschanz J, Norton M, Munger R, Welsh-Bohmer K, Zandi PP; Cache County Investigators.

Neurology. 2012 Oct 30;79(18):1846-52. doi: 10.1212/WNL.0b013e318271f823. Epub 2012 Oct 24.

30.

Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study.

Peters ME, Rosenberg PB, Steinberg M, Tschanz JT, Norton MC, Welsh-Bohmer KA, Hayden KM, Breitner JC, Lyketsos CG; Cache County Investigators.

Am J Geriatr Psychiatry. 2012 May;20(5):416-24. doi: 10.1097/JGP.0b013e318211057d.

31.

The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, Zandi PP, Breitner JC, Norton MC, Welsh-Bohmer KA, Zuckerman IH, Rattinger GB, Green RC, Corcoran C, Tschanz JT.

Int J Geriatr Psychiatry. 2012 Dec;27(12):1248-57. doi: 10.1002/gps.3769. Epub 2012 Feb 29.

32.

Lifestyle behavior pattern is associated with different levels of risk for incident dementia and Alzheimer's disease: the Cache County study.

Norton MC, Dew J, Smith H, Fauth E, Piercy KW, Breitner JC, Tschanz J, Wengreen H, Welsh-Bohmer K; Cache County Investigators.

J Am Geriatr Soc. 2012 Mar;60(3):405-12. doi: 10.1111/j.1532-5415.2011.03860.x. Epub 2012 Feb 8.

33.

Latent class-derived subgroups of depressive symptoms in a community sample of older adults: the Cache County Study.

Lee CT, Leoutsakos JM, Lyketsos CG, Steffens DC, Breitner JC, Norton MC.

Int J Geriatr Psychiatry. 2012 Oct;27(10):1061-9. doi: 10.1002/gps.2824. Epub 2011 Dec 2.

34.

Early parental death and remarriage of widowed parents as risk factors for Alzheimer disease: the Cache County study.

Norton MC, Smith KR, Østbye T, Tschanz JT, Schwartz S, Corcoran C, Breitner JC, Steffens DC, Skoog I, Rabins PV, Welsh-Bohmer KA; Cache County Investigators.

Am J Geriatr Psychiatry. 2011 Sep;19(9):814-24. doi: 10.1097/JGP.0b013e3182011b38.

35.

Atrial fibrillation and risk of dementia: a prospective cohort study.

Dublin S, Anderson ML, Haneuse SJ, Heckbert SR, Crane PK, Breitner JC, McCormick W, Bowen JD, Teri L, McCurry SM, Larson EB.

J Am Geriatr Soc. 2011 Aug;59(8):1369-75. doi: 10.1111/j.1532-5415.2011.03508.x. Epub 2011 Aug 1.

36.

Extended results of the Alzheimer's disease anti-inflammatory prevention trial.

Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN; ADAPT Research Group.

Alzheimers Dement. 2011 Jul;7(4):402-11. doi: 10.1016/j.jalz.2010.12.014.

37.

Further evidence for vascular mediation of Alzheimer's dementia pathogenesis?

Breitner JC.

Biol Psychiatry. 2011 Jul 15;70(2):113-4. doi: 10.1016/j.biopsych.2011.05.026. No abstract available.

PMID:
21708304
38.

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.

Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, Mielke MM, Piercy K, Steinberg M, Rabins PV, Leoutsakos JM, Welsh-Bohmer KA, Breitner JC, Lyketsos CG.

Am J Geriatr Psychiatry. 2011 Jun;19(6):532-42. doi: 10.1097/JGP.0b013e3181faec23.

39.

Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.

Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG; ADAPT Research Team.

Int J Geriatr Psychiatry. 2012 Apr;27(4):364-74. doi: 10.1002/gps.2723. Epub 2011 May 10.

40.

Cognitive stimulation and cognitive and functional decline in Alzheimer's disease: the cache county dementia progression study.

Treiber KA, Carlson MC, Corcoran C, Norton MC, Breitner JC, Piercy KW, Deberard MS, Stein D, Foley B, Welsh-Bohmer KA, Frye A, Lyketsos CG, Tschanz JT.

J Gerontol B Psychol Sci Soc Sci. 2011 Jul;66(4):416-25. doi: 10.1093/geronb/gbr023. Epub 2011 Mar 25.

41.

Histamine-2 receptor antagonist use and incident dementia in an older cohort.

Gray SL, Walker R, Dublin S, Haneuse S, Crane PK, Breitner JC, Bowen J, McCormick W, Larson EB.

J Am Geriatr Soc. 2011 Feb;59(2):251-7. doi: 10.1111/j.1532-5415.2010.03275.x.

42.

Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1.

Mayeux R, Reitz C, Brickman AM, Haan MN, Manly JJ, Glymour MM, Weiss CC, Yaffe K, Middleton L, Hendrie HC, Warren LH, Hayden KM, Welsh-Bohmer KA, Breitner JC, Morris JC.

Alzheimers Dement. 2011 Jan;7(1):15-34. doi: 10.1016/j.jalz.2010.11.005. Review.

43.

Apolipoprotein e, Alzheimer's disease, and amyloid: do we have the cart before the horse?

Breitner JC.

J Alzheimers Dis. 2011;23(1):171-2. doi: 10.3233/JAD-2010-101351. No abstract available.

PMID:
21228459
44.

Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques.

Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ.

Neurology. 2010 Sep 28;75(13):1203-10. doi: 10.1212/WNL.0b013e3181f52db1. Epub 2010 Sep 1.

45.

Greater risk of dementia when spouse has dementia? The Cache County study.

Norton MC, Smith KR, Østbye T, Tschanz JT, Corcoran C, Schwartz S, Piercy KW, Rabins PV, Steffens DC, Skoog I, Breitner JC, Welsh-Bohmer KA; Cache County Investigators.

J Am Geriatr Soc. 2010 May;58(5):895-900. doi: 10.1111/j.1532-5415.2010.02806.x. Erratum in: J Am Geriatr Soc. 2013 Sep;61(9):1642. J Am Geriatr Soc. 2012 May;60(5):1000.

46.

Age-varying association between statin use and incident Alzheimer's disease.

Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB.

J Am Geriatr Soc. 2010 Jul;58(7):1311-7. doi: 10.1111/j.1532-5415.2010.02906.x. Epub 2010 Jun 1.

47.

Occupational exposure to pesticides increases the risk of incident AD: the Cache County study.

Hayden KM, Norton MC, Darcey D, Ostbye T, Zandi PP, Breitner JC, Welsh-Bohmer KA; Cache County Study Investigators.

Neurology. 2010 May 11;74(19):1524-30. doi: 10.1212/WNL.0b013e3181dd4423.

48.

Association between APOE epsilon4 allele and vascular dementia: The Cache County study.

Chuang YF, Hayden KM, Norton MC, Tschanz J, Breitner JC, Welsh-Bohmer KA, Zandi PP.

Dement Geriatr Cogn Disord. 2010;29(3):248-53. doi: 10.1159/000285166. Epub 2010 Apr 6.

49.

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.

Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ.

Alzheimers Dement. 2010 Mar;6(2):89-97. doi: 10.1016/j.jalz.2010.01.008.

50.

Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.

Montine TJ, Sonnen JA, Milne G, Baker LD, Breitner JC.

PLoS One. 2010 Feb 19;5(2):e9340. doi: 10.1371/journal.pone.0009340.

Supplemental Content

Loading ...
Support Center